Meeting
2020 Gastrointestinal Cancers Symposium
Laparoscopic versus open total gastrectomy for clinical stage I gastric cancer: Morbidity and mortality results from a prospective randomized multicenter controlled trial (CLASS02).
Authors
Fenglin Liu
Zhongshan Hospital, Fudan University, Shanghai, China
Fenglin Liu , Changming Huang , Zekuan Xu , Xiangqian Su , Gang Zhao , Jianxin Ye , Xiaohui Du , Hua Huang , Jiankun Hu , Guoxin Li , Peiwu Yu , Yong Li , Jian Suo , Naiqing Zhao , Wei Zhang , Haojie Li , Hongyong He , Yihong Sun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03007550
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 378)
Abstract #
378
Poster Bd #
E11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Single-arm phase II trial to evaluate the safety of laparoscopic/robotic total gastrectomy with spleen-preserving splenic hilar dissection for locally advanced proximal gastric cancer that invades the greater curvature: JCOG1809.
First Author: Takahiro Kinoshita
Poster
2019 Gastrointestinal Cancers Symposium
The safety assessment of robotic versus laparoscopic gastrectomy for gastric cancer using a propensity score matching method.
First Author: Rie Makuuchi
Poster
2019 Gastrointestinal Cancers Symposium
Safety of laparoscopic total gastrectomy with splenectomy for upper third advanced gastric cancer.
First Author: Eigo Akimoto
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO.
First Author: Thorsten Goetze